|
1
|
Lundgren JD and Shelhamer JH: Pathogenesis
of airway mucus hypersecretion. J Allergy Clin Immunol. 85:399–417.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rogers DF: Mucus hypersecretion in chronic
obstructive pulmonary disease. Novartis Found Symp. 234:65–83.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou X, Tong J and Lan J: Chronic
obstructive pulmonary disease airway mucin molecular phenotypic
studies. Chin J Tuberc Respir Dis. 25:437–441. 2002.(In
Chinese).
|
|
4
|
Vestbo J: Epidemiological studies in mucus
hypersecretion. Novartis Found Symp. 248:3–19. 277–282. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rogers DF: Physiology of airway mucus
secretion and pathophysiology of hypersecretion. Respir Care.
52:1134–1149. 2007.PubMed/NCBI
|
|
6
|
Davis CW and Dickey B: Regulated airway
goblet cell mucin secretion. Annu Rev Physiol. 70:487–512. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rogers DF: Airway mucus hypersecretion in
asthma: an undervalued pathology? Curr Opin Pharmacol. 4:241–250.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cerveri I and Brusasco V: Revisited role
for mucus hypersecretion in the pathogenesis of COPD. Eur Respir
Rev. 19:109–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Burgel PR and Martin C: Mucus
hypersecretion in COPD: should we only rely on symptoms? Eur Respir
Rev. 19:94–96. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lai H and Rogers DF: New pharmacotherapy
for airway mucus hypersecretion in asthma and COPD: targeting
intracellular signaling pathways. J Aerosol Med Pulm Drug Deliv.
23:219–231. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rogers DF: Mucoactive agents for airway
mucus hypersecretory diseases. Respir Care. 52:1176–1197.
2007.PubMed/NCBI
|
|
12
|
Henke MO, Shah SA and Rubin BK: The role
of airway secretions in COPD - clinical applications. COPD.
2:377–390. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Disse B: Clinical evaluation of new
therapies for treatment of mucus hypersecretion in respiratory
diseases. Novartis Found Symp. 248:254–276. 277–282. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Evans CM and Koo JS: Airway mucus: the
good, the bad, the sticky. Pharmacol Ther. 121:332–348. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Voynow JA and Rubin BK: Mucins, mucus, and
sputum. Chest. 135:505–512. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morcillo EJ and Cortijo J: Mucus and MUC
in asthma. Curr Opin Pulm Med. 12:1–6. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
de Marco R, Accordini S, Cerveri I, et al:
Incidence of chronic obstructive pulmonary disease in a cohort of
young adults according to the presence of chronic cough and phlegm.
Am J Respir Crit Care Med. 175:32–39. 2007.PubMed/NCBI
|
|
18
|
Vestbo J and Hogg JC: Convergence of the
epidemiology and pathology of COPD. Thorax. 61:86–88. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Delmotte P, Degroote S, Lafitte JJ, et al:
Tumor necrosis factor alpha increases the expression of
glycosyltransferases and sulfotransferases responsible for the
biosynthesis of sialylated and/or sulfated Lewis × epitopes in the
human bronchial mucosa. J Biol Chem. 277:424–431. 2002.
|
|
20
|
Hogg JC, Chu FS, Tan WC, et al: Survival
after lung volume reduction in chronic obstructive pulmonary
disease: insights from small airway pathology. Am J Respir Crit
Care Med. 176:454–459. 2007.PubMed/NCBI
|
|
21
|
Rogers DF and Barnes PJ: Treatment of
airway mucus hypersecretion. Ann Med. 38:116–125. 2006. View Article : Google Scholar
|
|
22
|
Barnes PJ: Current and future therapies
for airway mucus hypersecretion. Novartis Found Symp. 248:237–253.
277–281. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lun Z: The market analysis of Ambroxol in
China. Chinese Pharmaceutical Information. 22:23–26. 2006.(In
Chinese).
|
|
24
|
Beeh KM, Beier J, Esperester A and Paul
LD: Antiinflammatory properties of ambroxol. Eur J Med Res.
13:557–562. 2008.PubMed/NCBI
|
|
25
|
Malerba M and Ragnoli B: Ambroxol in the
21st century: pharmacological and clinical update. Expert Opin Drug
Metab Toxicol. 4:1119–1129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dekhuijzen PN and van Beurden WJ: The role
for N-acetylcysteine in the management of COPD. Int J Chron
Obstruct Pulmon Dis. 1:99–106. 2006.PubMed/NCBI
|
|
27
|
Sadowska AM, Manuel-Y-Keenoy B and De
Backer WA: Antioxidant and anti-inflammatory efficacy of NAC in the
treatment of COPD: discordant in vitro and in vivo dose-effects: a
review. Pulm Pharmacol Ther. 20:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stav D and Raz M: Effect of
N-acetylcysteine on air trapping in COPD: a randomized
placebo-controlled study. Chest. 136:381–386. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pela R, Calcagni AM, Subiaco S, et al:
N-acetylcysteine reduces the exacerbation rate in patients with
moderate to severe COPD. Respiration. 66:495–500. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gerrits CM, Herings RM, Leufkens HG and
Lammers JW: N-acetylcysteine reduces the risk of re-hospitalisation
among patients with chronic obstructive pulmonary disease. Eur
Respir J. 21:795–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Millea PJ: N-acetylcysteine: multiple
clinical applications. Am Fam Physician. 80:265–269.
2009.PubMed/NCBI
|
|
32
|
Hooper C and Calvert J: The role for
S-carboxymethylcysteine (carbocisteine) in the management of
chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon
Dis. 3:659–669. 2008.PubMed/NCBI
|
|
33
|
Zheng JP, Kang J, Huang SG, et al: Effect
of carbocisteine on acute exacerbation of chronic obstructive
pulmonary disease (PEACE Study): a randomised placebo-controlled
study. Lancet. 371:2013–2018. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yasuda H, Yamaya M, Sasaki T, et al:
Carbocisteine reduces frequency of common colds and exacerbations
in patients with chronic obstructive pulmonary disease. J Am
Geriatr Soc. 54:378–380. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tatsumi K and Fukuchi Y; PEACE Study
Group. Carbocisteine improves quality of life in patients with
chronic obstructive pulmonary disease. J Am Geriatr Soc.
55:1884–1886. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hauber HP and Zabel P: Emerging mucus
regulating drugs in inflammatory and allergic lung disease. Inflamm
Allergy Drug Targets. 7:30–34. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li G, Cun X, Li L and Yongqing X: Advances
in studies on Platycodon grandiflorum. China Journal of
Chinese Materia Medica. 32:183–185. 2007.(In Chinese).
|
|
38
|
Bin Y, Yongqing X, Rixin L, Ruojing W, Wen
L, Cun Z, Ying C, Qianpeng W, Lan W and Yongyan W: Studies on
expectorant compounds in volatile oil from root and rhizome of
Aster tataricus. China Journal of Chinese Materia Medica.
33:281–283. 2008.(In Chinese).
|
|
39
|
Haiqing W, Hongwei K, Kang J, Jingli S,
Yan L, Jun T and Shiyou Y: Antitussive, expectorant and
antibacterial actions of Zhebei Zhike granules. Chinese Journal of
Experimental Traditional Medical Formulae. 17:207–210. 2011.(In
Chinese).
|
|
40
|
McKay A, Leung BP, McInnes IB, et al: A
novel anti-inflammatory role of simvastatin in a murine model of
allergic asthma. J Immunol. 172:2903–2908. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Weitz-Schmidt G: Statins as
anti-inflammatory agents. Trends Pharmacol Sci. 23:482–486. 2002.
View Article : Google Scholar
|
|
42
|
Wang HX, Sun B, Li JQ, et al: Effect of
simvastatin on airway mucus hypersecretion in rats and its
molecular mechanism. Di 3 Jun Yi Da Xue Xue Bao. 30:213–215.
2008.(In Chinese).
|
|
43
|
Søyseth V, Brekke PH, Smith P and Omland
T: Statin use is associated with reduced mortality in COPD. Eur
Respir J. 29:279–283. 2007.
|
|
44
|
Mancini GB, Etminan M, Zhang B, et al:
Reduction of morbidity and mortality by statins,
angiotensin-converting enzyme inhibitors, and angiotensin receptor
blockers in patients with chronic obstructive pulmonary disease. J
Am Coll Cardiol. 47:2554–2560. 2006. View Article : Google Scholar
|
|
45
|
Kitazaki T, Fukuda M, Soda H and Kohno S:
Novel effects of gefitinib on mucin production in
bronchioloalveolar carcinoma; two case reports. Lung Cancer.
49:125–128. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kitazaki T, Soda H, Doi S, et al:
Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small
cell lung cancer cells. Lung Cancer. 50:19–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guan AY, Xu ZB, Wen FQ, Wang BD and Feng
Y: Effect of gefinitib on airway mucus hypertension induced by
acrolein in rats. Sichuan Da Xue Xue Bao Yi Xue Ban. 39:231–234.
2008.(In Chinese).
|
|
48
|
Vignola AM: PDE4 inhibitors in COPD - a
more selective approach to treatment. Respir Med. 98:495–503. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kroegel C and Foerster M:
Phosphodiesterase-4 inhibitors as a novel approach for the
treatment of respiratory disease: cilomilast. Expert Opin Investig
Drugs. 16:109–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Michalski JM, Golden G, Ikari J and
Rennard SI: PDE4: a novel target in the treatment of chronic
obstructive pulmonary disease. Clin Pharmacol Ther. 91:134–142.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Moretti M, Bottrighi P, Dallari R, et al;
EQUALIFE Study Group. The effect of long-term treatment with
erdosteine on chronic obstructive pulmonary disease: the EQUALIFE
Study. Drugs Exp Clin Res. 30:143–152. 2004.PubMed/NCBI
|
|
52
|
Marchioni CF, Polu JM, Taytard A, et al:
Evaluation of efficacy and safety of erdosteine in patients
affected by chronic bronchitis during an infective exacerbation
phase and receiving amoxycillin as basic treatment (ECOBES,
European Chronic Obstructive Bronchitis Erdosteine Study). Int J
Clin Pharmacol Ther. 33:612–618. 1995.
|
|
53
|
Rhee CK, Kang CM, You MB, Yoon HK, Kim YK,
Kim KH, Moon HS, Park SH and Song JS: Effect of fudosteine on mucin
production. Eur Respir J. 32:1195–202. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xin S, Yi S, Zenghua X, Yong S and Gui Z:
A randomized controlled trial of expectorant in patients with
respiratory tract infection. Chinese Journal of New Drugs and
Clinical Remedies. 25:369–372. 2006.(In Chinese).
|
|
55
|
Li N, Li Q, Zhou XD, et al: The effect of
quercetin on human neutrophil elastase-induced mucin5AC expression
in human airway epithelial cells. Int Immunopharmacol. 14:195–201.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wu H, Li Q, Zhou X, et al: Theaflavins
extracted from black tea inhibit airway mucous hypersecretion
induced by cigarette smoke in rats. Inflammation. 35:271–279. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kwon SH, Nam JI, Kim SH, et al: Kaempferol
and quercetin, essential ingredients in Ginkgo biloba
extract, inhibit interleukin-1beta-induced MUC5AC gene expression
in human airway epithelial cells. Phytother Res. 23:1708–1712.
2009.PubMed/NCBI
|
|
58
|
Khan S, Liu YC, Khawaja AM, et al: Effect
of the long-acting tachykinin NK(1) receptor antagonist MEN 11467
on tracheal mucus secretion in allergic ferrets. Br J Pharmacol.
132:189–196. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shao MX and Nadel JA: Neutrophil elastase
induces MUC5AC mucin production in human airway epithelial cells
via a cascade involving protein kinase C, reactive oxygen species,
and TNF-alpha-converting enzyme. J Immunol. 15:4009–4016. 2005.
View Article : Google Scholar
|
|
60
|
Chughtai B and O’Riordan TG: Potential
role of inhibitors of neutrophil elastase in treating diseases of
the airway. J Aerosol Med. 17:289–298. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Feng L, Zhu W, Huang C and Li Y: Direct
interaction of ONO-5046 with human neutrophil elastase through
1H NMR and molecular docking. Int J Biol Macromol.
51:196–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tomiyama H, Takara I, Tokumine J and
Sugahara K: Sivelestat sodium hydrate was effective for ARDS in a
patient suffering from chronic rheumatoid arthritis with acute
exacerbation after failing to respond to high dose steroid pulse
therapy. Masui. 53:1042–1046. 2004.(In Japanese).
|
|
63
|
Hubeau C, Singer M, Lagranderie M, et al:
Extended freeze-dried Mycobacterium bovis Bacillus
Calmette-Guérin induces the release of interleukin-12 but not
tumour necrosis factor-α by alveolar macrophages, both in
vitro and in vivo. Clin Exp Allergy. 33:386–393.
2003.PubMed/NCBI
|
|
64
|
Cheng G, Arima M, Honda K, et al:
Anti-interleukin-9 antibody treatment inhibits airway inflammation
and hyperreactivity in mouse asthma model. Am J Respir Crit Care
Med. 166:409–416. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Tomkinson A, Tepper J, Morton M, Bowden A,
Stevens L, Harris P, Lindell D, Fitch N, Gundel R and Getz EB:
Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in
a monkey model of asthma. Allergy. 65:69–77. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cook ML and Bochner BS: Update on
biological therapeutics for asthma. World Allergy Organ J.
3:188–94. 2010.PubMed/NCBI
|
|
67
|
Sabater JR, Mao YM, Shaffer C, et al:
Aerosolization of P2Y(2)-receptor agonists enhances mucociliary
clearance in sheep. J Appl Physiol (1985). 87:2191–2196.
1999.PubMed/NCBI
|
|
68
|
Yerxa BR, Sabater JR, Davis CW, et al:
Pharmacology of INS37217 [P(1)-(uridine 5′)-P(4)- (2′-deoxycytidine
5′)tetraphosphate, tetrasodium salt], a next-generation P2Y(2)
receptor agonist for the treatment of cystic fibrosis. J Pharmacol
Exp Ther. 302:871–880. 2002.
|
|
69
|
Kellerman DJ: P2Y(2) receptor agonists: a
new class of medication targeted at improved mucociliary clearance.
Chest. 121(5 Suppl): 201S–205S. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Poole P, Black PN and Cates CJ: Mucolytic
agents for chronic bronchitis or chronic obstructive pulmonary
disease. Cochrane Database Syst Rev. 8:CD0012872012.
|
